This is a paid advertisement on behalf of FendX Technologies Inc.
Today, we have FendX Technologies CEO Carolyn Myers with us and we are excited to learn more about her company.
Can you please tell our readers about FendX Technologies and the markets that it is focused on?
FendX Technologies Inc. is a nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. We are developing both film and spray products to protect surfaces from contamination. Our lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. FendX believes REPELWRAP™ film will have applications in healthcare settings and other high-traffic high-touch point industries. Our spray nanotechnology is also being developed to reduce contamination on surfaces by both repelling and killing pathogens. It is similar to REPELWRAP™ film in that when a surface is sprayed with the nanotechnology it forms a film coating with essentially the same repelling properties as REPELWRAP™ film, as well as having the kill property. We believe the spray nanotechnology is important to the development of our product pipeline as a spray could be easier to apply to many surfaces and expand our potential market opportunities.
What separates FendX Technologies from other companies that are focused on the same sector?
FendX believes its nanotechnology is unique and differentiated from current protective coatings in the marketplace as it instantly repels and prevents colony formation of key pathogens like MRSA and is effective in instantly repelling SARS-CoV-2 related viruses. Several competitive films incorporate metal ions like copper or silver in their films that kills bacteria and viruses when they come in contact with the surface. However, inactivation can take hours or potentially even days, leaving people at risk of being exposed to these contaminated surfaces until the bacteria or viruses are killed. Other competitive films require activation by light or other activators to kill pathogens that come into contact with the surface of the activated film. FendX believes REPELWRAP™ film will be the first film coating that instantly repels bacteria and viruses reducing the likelihood of people being contaminated when they touch surfaces coated with it.
How many people are on the FendX team? Who are some of the most important executives in the organization and what is their expertise?
FendX has a team of 12 staff, consultants and directors who are focused on continuing to successfully grow the organization.
Key executive staff include:
Dr. Carolyn Myers is the CEO, president and director of FendX. She is an accomplished senior executive with extensive experience creating, leading and growing healthcare businesses. She has held positions in large cap pharmaceutical companies including President of Dey Laboratories, President of Mylan Technologies Inc. (both acquired by Pfizer) and Vice President International Business Development and Alliance Management at Allergan PLC (acquired by Abbvie). Prior to serving in these roles, Dr. Myers served in various senior management positions in sales and marketing at Pharmacia Corporation (acquired by Pfizer). She earned her PhD in genetics from the University of British Columbia and her MBA from Rutgers University. Dr. Myers is a director of Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) and of EyeD Pharma.
Andrea Mulder is the COO of FendX. She is an experienced senior commercial healthcare executive with sales and marketing expertise leading launch strategies at large cap pharmaceutical and biotechnology companies. She has significant therapeutic knowledge across multiple therapeutic areas and has been an active member of leadership and commercial teams at Eisai Canada, Ipsen, GlaxoSmithKline, Roche, Johnson and Johnson and Pfizer in Canada. Ms. Mulder earned her degree at the University of Toronto in Health Sciences-Kinesiology and her EMBA at the University of Fredericton, New Brunswick.
Rose Zanic is the CFO of FendX. She has over 25 years of experience in capital markets and corporate finance. She is a self-employed corporate finance professional with significant experience advising Canadian public companies with financing, M&A transactions and providing public company administration. She previously spent 19 years with Wolverton Securities Ltd. where she was Senior Vice-President, Corporate Finance in charge of that firm’s corporate finance and syndication departments. Ms. Zanic holds a CPA, CA designation and received a Bachelor of Commerce degree from the University of British Columbia. She currently is a director and/or officer of several Canadian publicly listed companies and is also a member of the TSX Venture Exchange BC Local Advisory Committee.
What are the most significant potential catalysts for the business?
REPELWRAP™ film: This is our lead product under development. In June 2023, FendX announced its manufacturing partner, Dunmore International Corp. (“Dunmore”), a Steel Partners Holdings L.P. (NYSE: SPLP) operating company, successfully replicated film production in their R&D lab and are now progressing to automating the manufacturing process to conduct small runs on their commercial manufacturing line to create intermediate sized films for testing, including testing in real world conditions. If intermediate scale-up can be demonstrated, FendX intends to move to the commercial scale-up phase with a third-party manufacturer to create a commercial product, which would be tested to ensure it meets the repelling, durability, and stability specifications. If successful, the Company intends to commercialize this product using distributor partnerships still to be entered into. The Company estimates the commercial launch of REPELWRAP™ film in the Canadian market in mid-2024, conditional on achieving successful scale-up assessment, product scale-up and commercial manufacturing. After launching in Canada, the Company intends to seek any required approvals for launch in the United States as well as certain European and Asian countries in the longer term.
Spray Nanotechnology: The project is in an early stage of development in collaboration with McMaster University. When sprayed onto a surface, it forms a protective film coating similar to REPELWRAP™ film and demonstrates similar repelling properties to REPELWRAP™ film. In addition, it effectively inactivates residual pathogens on the coated surface. We are working with McMaster to further develop the spray nanotechnology and believe a future spray product will be important to control the spread of pathogens on surfaces prone to contamination, as a potential spray product could be easier to apply to many surfaces and may expand potential market applications. When an advanced lab prototype spray has been developed, the Company intends to engage a third-party manufacturer to conduct intermediate scale-up development work and, upon further success, proceed to commercial scale-up work, like what is required to scale-up and commercialize the REPELWRAPTM film. To-date, the Company has not entered into any agreements with third parties for scale-up assessment, intermediate scale-up work or manufacturing.
Other Potential Products: The Company is also exploring additional applications of their nanotechnology, including development of enhancements to the current REPELWRAP™ film to create follow-on films including films with both repelling and killing properties. Also, FendX plans to assess the nanotechnology to develop a coating for catheters to prevent catheter-related blood clot or bacterial biofilm formation and occlusion. To date, FendX in collaboration with McMaster are in early-stage research to assess these additional applications, and we believe they could be important additions to our current projects as they may lead to expanded applications of our nanotechnology.
What assets are owned by the company and which products generate the most revenue for the business?
We are a development stage company not yet generating revenue. Our lead product is REPELWRAP™ film which is currently being assessed for automating the manufacturing process to create intermediate sized films for testing could lead to a commercial product and potential revenue in mid-2024. FendX holds an exclusive worldwide license to its nanotechnology and IP portfolio from McMaster, which encompasses both the film and spray coating nanotechnology formulations. FendX is focused on continuing to build on these licensed patents to protect its products in development, and future IP created from projects funded by FendX will be owned by FendX.
Company Relationship Disclosure
OTB is responsible for the OTB opinions provided in this disclosure except all sources or information provided by other parties were not verified or authenticated and OTB does not undertake to confirm or substantiate or be responsible for such information provided by other parties.
Any Content posted regarding a Profiled Issuer is not a solicitation or recommendation to buy, sell or hold securities. We cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. All information should be independently verified. We are not responsible for errors or omissions in our publications, and any opinions expressed are subject to change, without notice. We do not, nor are we under any obligation to undertake due diligence or investigation or authenticate and verify whatsoever regarding Profiled Issuers or any Content posted in relation thereto and we do not receive any verification from the Profiled Issuer regarding the Content we disseminate. Similarly, while we endeavor to facilitate the provision of quality information, we are not responsible for any loss or damages caused or alleged to have been caused by its use nor verify or authenticate or update such information.
Pursuant to an agreement between Spotlight Media and FendX Technologies Inc. we have been hired for a period of 30 days beginning August 1, 2023 and ending September 1, 2023 to publicly disseminate information about FendX Technologies Inc. including on the Website and other media including Facebook and Twitter. We are being paid $3,500 per month by FendX Technologies Inc. and were paid “ZERO” shares of unrestricted or restricted common shares. We may buy or sell additional shares of FendX Technologies in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
FendX Technologies Inc. Forward Looking Statement:
Certain statements contained in these marketing materials constitute forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”). These statements relate to future events or the future performance of FendX Technologies Inc. (“FendX” or the “Company”). All statements other than statements of historical fact are forward-looking statements. The use of any of the words “anticipate”, “plan”, “aim”, “target”, “contemplate”, “continue”, “estimate”, “expect”, “intend”, “propose”, “might”, “may”, “will”, “shall”, “project”, “should”, “could”, “would”, “believe”, “predict”, “forecast”, “pursue”, “potential”, “possible”, and similar expressions are intended to identify forward-looking statements. Forward-looking statements, included or referred to in these marketing materials include, but are not limited to statements with respect to: the business and financial prospects and opportunities of FendX; expectations regarding industry trends, overall market growth rates and FendX’s growth rates and growth strategies; the performance of FendX’s business and operations, including its research and development and scale up initiatives; FendX’s expectations regarding commercialization; FendX’s expectations regarding revenues, expenses and anticipated cash needs; FendX’s expectations regarding its target markets and industries; FendX’s intention to grow its business, operations and intellectual property portfolio; the expected timing and completion of FendX’s near-term objectives; laws and regulations and any amendments thereto applicable to FendX, its business, operations and financial results; FendX’s competitive advantages and business strategies; and other assumptions inherent in management’s expectations in respect of the forward-looking statements identified herein.
The forward-looking statements reflect FendX’s beliefs and assumptions with respect to, among other things, future operating and financial results; the accuracy of financial and operational projections; the impact of the international or global events, including government responses related thereto on demand for FendX’s products and FendX’s operations generally; general economic and industry conditions; future growth in world-wide demand for FendX’s products; FendX’s ability to obtain and retain qualified and diverse personnel in a timely and cost-efficient manner or at all; the regulatory framework governing FendX’s operations in the jurisdictions in which FendX conducts and will conduct its business; the development and performance of new products and technology; FendX’s ability to obtain financing on acceptable terms; inflation and changes to interest rates and their impact on FendX; the impact of increasing competition on FendX; the impact of changes in government policies on FendX; FendX’s ability to generate sufficient cash flow to meet its current and future obligations; product supply and demand; FendX’s ability to successfully implement the plans and programs disclosed in FendX’s strategy and other assumptions inherent in management’s expectations in respect of the forward-looking statements identified herein.
The forward-looking statements contained in this document represent FendX’s expectations as of the date hereof and are subject to change after such date. FendX disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as may be required by applicable laws. Readers are cautioned that the foregoing lists are not exhaustive. For a full discussion of our material risk factors, see “Risk Factors” in FendX’s management’s discussion and analysis for the three months ended March 31, 2023, and “Risk Factors” in FendX’s long form prospectus dated January 31, 2023, each as filed on SEDAR+ at www.sedarplus.ca.
Additional Disclosures
This is a paid advertisement on behalf of FendX Technologies Inc.
Certain statements contained in these marketing materials constitute forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”). These statements relate to future events or the future performance of FendX Technologies Inc. (“FendX” or the “Company”). All statements other than statements of historical fact are forward-looking statements. The use of any of the words “anticipate”, “plan”, “aim”, “target”, “contemplate”, “continue”, “estimate”, “expect”, “intend”, “propose”, “might”, “may”, “will”, “shall”, “project”, “should”, “could”, “would”, “believe”, “predict”, “forecast”, “pursue”, “potential”, “possible”, and similar expressions are intended to identify forward-looking statements. Forward-looking statements, included or referred to in these marketing materials include, but are not limited to statements with respect to: the business and financial prospects and opportunities of FendX; expectations regarding industry trends, overall market growth rates and FendX’s growth rates and growth strategies; the performance of FendX’s business and operations; FendX’s expectations regarding revenues, expenses and anticipated cash needs; FendX’s intention to grow its business and operations; the expected timing and completion of FendX’s near-term objectives; laws and regulations and any amendments thereto applicable to FendX, its business, operations and financial results; FendX’s competitive advantages and business strategies; and other assumptions inherent in management’s expectations in respect of the forward-looking statements identified herein.
The forward-looking statements reflect FendX’s beliefs and assumptions with respect to, among other things, future operating and financial results; the accuracy of financial and operational projections; the impact of the international or global events, including government responses related thereto on demand for FendX’s products and FendX’s operations generally; general economic and industry conditions; future growth in world-wide demand for FendX’s products; FendX’s ability to obtain and retain qualified and diverse personnel in a timely and cost-efficient manner or at all; the regulatory framework governing FendX’s operations in the jurisdictions in which FendX conducts and will conduct its business; the development and performance of new products and technology; FendX’s ability to obtain financing on acceptable terms; inflation and changes to interest rates and their impact on FendX; the impact of increasing competition on FendX; the impact of changes in government policies on FendX; FendX’s ability to generate sufficient cash flow to meet its current and future obligations; product supply and demand; FendX’s ability to successfully implement the plans and programs disclosed in FendX’s strategy and other assumptions inherent in management’s expectations in respect of the forward-looking statements identified herein.
The forward-looking statements contained in this document represent FendX’s expectations as of the date hereof and are subject to change after such date. FendX disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as may be required by applicable laws. Readers are cautioned that the foregoing lists are not exhaustive. For a full discussion of our material risk factors, see “Risk Factors” in FendX’s management’s discussion and analysis for the three months ended March 31, 2023, and “Risk Factors” in FendX’s long form prospectus dated January 31, 2023, each as filed on SEDAR+ at www.sedarplus.ca.
